CYP1B1 enhances the resistance of epithelial ovarian cancer cells to paclitaxel in vivo and in vitro

Ovarian cancer (OC) is the most frequent cause of mortality among gynecological malignancies, with a 5-year survival rate of approximately 30%. The standard regimen for OC therapy includes a platinum agent combined with a taxane, to which the patients frequently acquire resistance. Resistance arises...

Descripción completa

Detalles Bibliográficos
Autores principales: ZHU, ZHUANGYAN, MU, YAQIN, QI, CAIXIA, WANG, JIAN, XI, GUOPING, GUO, JUNCHENG, MI, RUORAN, ZHAO, FUXI
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2015
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4292762/
https://www.ncbi.nlm.nih.gov/pubmed/25516145
http://dx.doi.org/10.3892/ijmm.2014.2041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4292762/
https://www.ncbi.nlm.nih.gov/pubmed/25516145
http://dx.doi.org/10.3892/ijmm.2014.2041

Ejemplares similares